ストックスクリーナーアプリを入手
0.489
2.28%
0.0109
前日終値:
$0.4781
開ける：
$0.49
24時間の取引高:
9,844
Relative Volume:
0.24
時価総額：
$10.02M
収益：
$2.82M
当期純損益:
$-14.20M
株価収益率:
-0.5753
EPS:
-0.85
ネットキャッシュフロー:
$-15.13M
1週間 パフォーマンス:
-2.53%
1か月 パフォーマンス:
-8.58%
6か月 パフォーマンス:
-36.49%
1年 パフォーマンス:
-52.52%
1日の値動き範囲:
$0.4509
$0.51
1週間の範囲:
$0.4509
$0.512
52週間の値動き範囲:
$0.45
$1.19
Talphera Inc Stock (TLPH) Company Profile
TLPH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.489 | 10.29M | 2.82M | -14.20M | -15.13M | -0.85 |
|
HLN
Haleon Plc Adr
|
11.14 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.62 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8368 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.30 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2020-07-20 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2019-11-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-05 | 再開されました | Credit Suisse | Outperform |
| 2019-07-10 | 再開されました | Credit Suisse | Outperform |
| 2019-04-24 | 再開されました | B. Riley FBR | Buy |
| 2019-02-15 | 開始されました | Credit Suisse | Outperform |
| 2018-10-23 | 開始されました | B. Riley FBR | Buy |
| 2017-10-13 | ダウングレード | Jefferies | Buy → Hold |
| 2017-10-13 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-07-14 | 再開されました | Jefferies | Buy |
| 2016-09-15 | 繰り返されました | ROTH Capital | Buy |
| 2016-08-05 | ダウングレード | Stifel | Buy → Hold |
| 2015-10-30 | アップグレード | Jefferies | Hold → Buy |
| 2015-10-05 | 繰り返されました | ROTH Capital | Buy |
| 2015-09-02 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-10 | 再開されました | ROTH Capital | Buy |
| 2015-05-06 | 繰り返されました | Mizuho | Neutral |
| 2015-05-05 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-03-10 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-03-09 | ダウングレード | Mizuho | Buy → Neutral |
すべてを表示
Talphera Inc (TLPH) 最新ニュース
Financial Review: Talphera (NASDAQ:TLPH) & Alterity Therapeutics (NASDAQ:ATHE) - Defense World
Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript - MSN
Talphera’s Strategic Advancements and Financial Stability Reinforce Buy Rating - TipRanks
Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing - MSN
Talphera, Inc. Earnings Call: Strategic Adjustments and Financial Progress - TipRanks
TLPH Prepares to Finalize NEPHRO CRRT Registration Trial | TLPH Stock News - GuruFocus
Talphera: Q1 Earnings Snapshot - Greenwich Time
Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and FDA ... - Yahoo Finance
Talphera, Inc. Reports Q1 2025 Financial Results - TipRanks
Talphera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025 - Investing.com Nigeria
TLPH Reports Strong Q1 Revenue with Promising Study Progress | T - GuruFocus
Talphera Inc Reports Q1 2025 EPS Loss of $0.10, Beating Estimates; Revenue Details Unavailable - GuruFocus
TALPHERA, INC. SEC 10-Q Report - TradingView
TLPH Reports Strong Q1 Revenue with Promising Study Progress | TLPH Stock News - GuruFocus
Talphera Announces First Quarter 2025 Financial Results and Prov - GuruFocus
Talphera Cuts Net Loss 32%, Secures FDA Approval for Streamlined Clinical Trial Design - Stock Titan
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | TLPH Stock News - GuruFocus
Talphera reports Q1 EPS (10c), consensus (14c) - TipRanks
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 - Citizen Tribune
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 | TLPH Stock News - GuruFocus
All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy - Yahoo Finance
HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
HC Wainwright Estimates Talphera FY2029 Earnings - Defense World
Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks
Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com Canada
Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Talphera Inc (TLPH) 財務データ
収益
当期純利益
現金流量
EPS
Talphera Inc (TLPH) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Aslam Shakil | Chief Medical Officer |
Jun 14 '24 |
Buy |
1.07 |
5,000 |
5,357 |
37,695 |
| Aslam Shakil | Chief Medical Officer |
Jun 13 '24 |
Buy |
0.98 |
695 |
681 |
32,695 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Dec 05 '24 |
Buy |
0.64 |
5,000 |
3,200 |
208,066 |
| ASADORIAN RAFFI | Chief Financial Officer |
Dec 02 '24 |
Sale |
0.77 |
155 |
119 |
37,578 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Nov 27 '24 |
Buy |
0.73 |
5,000 |
3,650 |
203,066 |
3.28%
2.99%
大文字化:
|
ボリューム (24 時間):